Animal Drug and Animal Generic Drug User Fee Amendments of 2023

3/12/2024, 7:30 AM

Animal Drug and Animal Generic Drug User Fee Amendments of 2023

This bill reauthorizes the Food and Drug Administration (FDA) to collect fees for brand-name and generic animal drug applications through FY2028. It also makes related updates to fee calculations and FDA reporting requirements.

The bill also (1) provides for a specific fee for requests to establish generic investigational new animal drug files and requires other application fees to be adjusted accordingly; (2) authorizes the FDA to remove species from the definition of major species (currently horses, dogs, cats, cattle, pigs, chickens, and turkeys); (3) provides statutory authority for the FDA to report on its progress supporting antimicrobial stewardship in veterinary settings (i.e., supporting responsible use of antimicrobial drugs for animals to slow the development of drug-resistant bacteria); and (4) provides for the regulation of zootechnical animal food substances as food additives (zootechnical animal food substances are added to the food or drinking water of animals to affect the byproducts of the animal's digestion, reduce foodborne pathogens, or alter the animal's gastrointestinal biome).

Animal drugs are drugs that are intended for animals other than humans (e.g., pets and livestock). Animal drugs must be approved by the FDA before they may be offered on the commercial market. The FDA is authorized to collect fees for animal drug applications in order to support its regulatory activities; this authority currently expires at the end of FY2023.

Bill 118 s 1844, also known as the Animal Drug and Animal Generic Drug User Fee Amendments of 2023, is a piece of legislation currently being considered by the US Congress. The bill aims to make amendments to the Animal Drug User Fee Act (ADUFA) and the Animal Generic Drug User Fee Act (AGDUFA) in order to improve the regulation and approval process for animal drugs.

One of the key provisions of the bill is the reauthorization of user fees for animal drug and animal generic drug applications. These fees are paid by drug manufacturers to the Food and Drug Administration (FDA) in order to help fund the review and approval process for new animal drugs. The bill also includes provisions to increase transparency and accountability in the FDA's review process, as well as measures to improve communication between the FDA and drug manufacturers.

Additionally, the bill includes provisions to enhance the safety and effectiveness of animal drugs, including requirements for post-market surveillance and reporting of adverse events. The bill also aims to streamline the approval process for generic animal drugs, in order to increase competition and lower costs for consumers. Overall, Bill 118 s 1844 seeks to improve the regulation and approval process for animal drugs in order to ensure the safety and effectiveness of these products for both animals and humans. The bill is currently being debated in Congress, and its ultimate fate will depend on the outcome of these deliberations.
Congress
118

Number
S - 1844

Introduced on
2023-06-07

# Amendments
0

Sponsors
+5

Cosponsors
+5

Variations and Revisions

7/26/2023

Status of Legislation

Bill Introduced
Introduced to House
House to Vote
Introduced to Senate
Senate to Vote

Purpose and Summary

Animal Drug and Animal Generic Drug User Fee Amendments of 2023

This bill reauthorizes the Food and Drug Administration (FDA) to collect fees for brand-name and generic animal drug applications through FY2028. It also makes related updates to fee calculations and FDA reporting requirements.

The bill also (1) provides for a specific fee for requests to establish generic investigational new animal drug files and requires other application fees to be adjusted accordingly; (2) authorizes the FDA to remove species from the definition of major species (currently horses, dogs, cats, cattle, pigs, chickens, and turkeys); (3) provides statutory authority for the FDA to report on its progress supporting antimicrobial stewardship in veterinary settings (i.e., supporting responsible use of antimicrobial drugs for animals to slow the development of drug-resistant bacteria); and (4) provides for the regulation of zootechnical animal food substances as food additives (zootechnical animal food substances are added to the food or drinking water of animals to affect the byproducts of the animal's digestion, reduce foodborne pathogens, or alter the animal's gastrointestinal biome).

Animal drugs are drugs that are intended for animals other than humans (e.g., pets and livestock). Animal drugs must be approved by the FDA before they may be offered on the commercial market. The FDA is authorized to collect fees for animal drug applications in order to support its regulatory activities; this authority currently expires at the end of FY2023.

Bill 118 s 1844, also known as the Animal Drug and Animal Generic Drug User Fee Amendments of 2023, is a piece of legislation currently being considered by the US Congress. The bill aims to make amendments to the Animal Drug User Fee Act (ADUFA) and the Animal Generic Drug User Fee Act (AGDUFA) in order to improve the regulation and approval process for animal drugs.

One of the key provisions of the bill is the reauthorization of user fees for animal drug and animal generic drug applications. These fees are paid by drug manufacturers to the Food and Drug Administration (FDA) in order to help fund the review and approval process for new animal drugs. The bill also includes provisions to increase transparency and accountability in the FDA's review process, as well as measures to improve communication between the FDA and drug manufacturers.

Additionally, the bill includes provisions to enhance the safety and effectiveness of animal drugs, including requirements for post-market surveillance and reporting of adverse events. The bill also aims to streamline the approval process for generic animal drugs, in order to increase competition and lower costs for consumers. Overall, Bill 118 s 1844 seeks to improve the regulation and approval process for animal drugs in order to ensure the safety and effectiveness of these products for both animals and humans. The bill is currently being debated in Congress, and its ultimate fate will depend on the outcome of these deliberations.
Alternative Names
Official Title as IntroducedA bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize user fee programs relating to new animal drugs and generic new animal drugs.

Policy Areas
Health

Potential Impact
Research and development•
User charges and fees•
Veterinary medicine and animal diseases

Comments

Recent Activity

Latest Summary11/7/2024

Animal Drug and Animal Generic Drug User Fee Amendments of 2023

This bill reauthorizes the Food and Drug Administration (FDA) to collect fees for brand-name and generic animal drug applications through FY2028. It also makes ...


Latest Action7/26/2023
Placed on Senate Legislative Calendar under General Orders. Calendar No. 174.